The present application is a 35 U.S.C. §371 national stage filing of International Patent Application No. PCT/CN2008/000865, filed Apr. 28, 2008, and through which priority is claimed to Chinese Patent Application No. 200710040140.1, filed Apr. 27, 2007, the disclosures of which are incorporated herein by reference in their entireties.
The invention belongs to the field of pharmacokinetics, particularly involves a detection method of blood plasma schizadrin B of strengthening body resistance and dissipating blood stasis botanical (vegetable).
Strengthening body resistance and dissipating blood stasis botanical are composed of compound prescriptions including salvia miltiorrhiza, peach kernel, Schisandra chinens etc., which have the effect of curing liver, lung and kidney fibrosis; however, due to lack of pharmacokinetics research has been carried out on the strengthening body resistance and dissipating blood stasis botanical, so it is not clear about the effective ingredients in vivo, and it is difficult to provide a basis for quality control and guiding clinical rational administration, thus hinder those drugs from entering the international market.
So far, no pharmacokinetics research report on the strengthening body resistance and dissipating blood stasis botanical has been found, and there has not any detection method of schizadrin B of the compound prescription in biological samples (including blood plasma).
The technical matters aim to be resolved by this invention is to provide a detection method of blood plasma schizadrin B of strengthening body resistance and dissipating blood stasis botanical (vegetable), and the method is used for pharmacokinetics research, and clarifying the pharmacokinetics rules of the blood plasma schizadrin B of strengthening body resistance and dissipating blood stasis botanical (vegetable).
The technical problems solved by the invention are achieved through the following technical solutions:
Detection method of blood plasma schizadrin B of strengthening body resistance and dissipating blood stasis botanical includes the following steps:
UPLC condition: chromatographic column: ACQUITY UPLC BEH C18 (a type of chromatographic column), 2.1×100 mm, mobile phase A: Water-Acetonitrile-Formic acid 95:5:0.1 v/v/v, mobile phase B: Acetonitrile-Formic acid 100:0.1 v/v; MS condition: electrospray ionization (ESI) ion source, detection with positive ion mode, scanning at the range of m/z 150 to 1200.
The described step (2) detects with the positive ion mode; the desolvation gas flow is 440 L/h, the desolvation gas temperature is 300° C., the cone gas flow is 50 L/h, the ion source temperature is 100° C., the spray capillary voltage is 3800 V, the sampling cone voltage is 30V, the extracting cone voltage is 2.00 V, the lens voltage is 0.1 V, and the mass scanning at the range of m/z 150 to 1200.
In the process of the liquid-liquid extraction in this invention, the detected components are distributed in two solvents which are immiscible, select appropriate organic solvents and appropriate proportion, can extract the non-polar components dissolved in the blood plasma entering the organic phase, and then the draining and enriching the organic phase; a UPLC system is used to separate analyte with other components, and finally detected with a mass spectrometric detector.
The ethyl acetate liquid-liquid extraction method adopted by the invention can extract the schizadrin B in the blood plasma, combined with using a UPLC/MS system to detect, markedly improve the resolutions of schizadrin B among other ingredients in the samples, and the analysis method is more sensitive and faster, to facilitate detection of the plasma concentration of the schizadrin B in pharmacokinetic research.
Combined with the specific embodiments, further elaboration of this invention is given below. It should be understood that these embodiments are only for description of the present invention but not for the use of limiting the scope of the present invention. It should also be understood that, after reading the contents taught in this invention, technicians in this field can make various changes or modifications to this invention, these equivalent forms are all included in the scope defined by the claims attached to this application.
A detection method of blood plasma schizadrin B of strengthening body resistance and dissipating blood stasis botanical includes:
1. Mammal plasma containing drugs after being administered the strengthening body resistance and dissipating blood stasis botanical was extracted with ethyl acetate with the volume ratio of 1:4, whirling for 3 min, then centrifugating at 9600 rpm for 10 min, and drying and enriching the supernatant under the condition of 25 to 30° C., redissolving the eluent with mobile phase and then analyzing it with UPLC/MS.
2. UPLC/MS detecting method: the analysis conditions of the UPLC/MS method adopted in this invention: chromatographic column: ACQUITY UPLC BEH C18 (a type of chromatographic column), 2.1×100 mm, mobile phase A: Water-Acetonitrile-Formic acid 95:5:0.1 v/v/v, mobile phase B: Acetonitrile-Formic acid 100:0.1 v/v, eluting in accordance with the following gradient:
MS conditions: electrospray ionization (ESI) ion source, detecting with positive ion mode; the desolvation gas flow is 440 L/h, the desolvation temperature is 300° C., the cone gas flow is 50 L/h, the ion source temperature is 100° C., the spray capillary voltage is 3800 V, the sampling cone voltage is 30V, the extracting cone voltage is 2.00 V, the lens voltage is 0.1 V, and the mass scanning at the range of m/z 150 to 1200.
Detection results: Schizadrin B can be detected in the plasma of mammals after drenched with strengthening body resistance and dissipating blood stasis botanical (see
Number | Date | Country | Kind |
---|---|---|---|
2007 1 0040140 | Apr 2007 | CN | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/CN2008/000865 | 4/28/2008 | WO | 00 | 10/27/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2008/131647 | 11/6/2008 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
20070160626 | Zhang et al. | Jul 2007 | A1 |
20100093099 | Ma et al. | Apr 2010 | A1 |
20100093103 | Ma et al. | Apr 2010 | A1 |
20100119541 | Xu et al. | May 2010 | A1 |
Number | Date | Country |
---|---|---|
1243743 | Feb 2000 | CN |
99113887.2 | Aug 2001 | CN |
1472532 | Feb 2004 | CN |
1669573 | Sep 2005 | CN |
02136002.2 | Sep 2005 | CN |
1839996 | Oct 2006 | CN |
1925864 | Mar 2007 | CN |
1959409 | May 2007 | CN |
101042380 | Sep 2007 | CN |
2007100401416 | Sep 2007 | CN |
101078712 | Nov 2007 | CN |
200710040331.8 | Dec 2009 | CN |
200510028951.0 | Mar 2010 | CN |
1165583 | Jun 1989 | JP |
20060038027 | May 2006 | KR |
0141778 | Jun 2001 | WO |
2004014409 | Feb 2004 | WO |
2007020382 | Feb 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20100093103 A1 | Apr 2010 | US |